Blockchain Registration Transaction Record

Lexaria Bioscience Announces Promising Results in Ongoing Animal Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) announces promising results from ongoing animal study WEIGHT-A24-1, showing top performers in reducing blood sugar levels. The study's focus on DehydraTECH-liraglutide and DehydraTECH-CBD formulations could lead to more effective solutions for diabetic control.

Lexaria Bioscience Announces Promising Results in Ongoing Animal Study

This news matters to individuals interested in diabetes treatment and drug delivery technology. The promising results could potentially lead to more effective solutions for diabetic control, offering hope to those affected by the condition. Additionally, it reflects the innovation and progress in drug delivery technology, which could have broader implications in the pharmaceutical industry.

BlockchainDetails
Contract Address0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71
Transaction ID0x1ee778ce0e845a5fccf0258376a8f86e68f9b9a62fb402c71c95ccafc0e60c63
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital Fingerprintfilo3_Xp-1e4e7c463683e428ce851ed2dd4c19a5